Kevin Patrick Danahy - 02 Oct 2025 Form 4 Insider Report for PULSE BIOSCIENCES, INC. (PLSE)

Role
Chief Commercial Officer
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
02 Oct 2025
Net transactions value
-$78,200
Form type
4
Filing time
07 Oct 2025, 19:18:44 UTC
Previous filing
22 Sep 2025
Next filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Danahy Kevin Patrick Chief Commercial Officer C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD /s/ Kenneth B. Stratton, as Attorney-in-Fact 07 Oct 2025 0001913245

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLSE Common Stock Options Exercise $7,038 +4,600 +11% $1.53 47,898 02 Oct 2025 Direct F1
transaction PLSE Common Stock Sale $85,238 -4,600 -9.6% $18.53 43,298 02 Oct 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Options Exercise $0 -4,600 -1.1% $0.000000 425,000 02 Oct 2025 Common Stock 4,600 $1.53 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
F2 The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $18.48 to $18.65 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
F3 Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.